Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 3:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 77 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Angina Patients With Non-obstructive Coronary Artery Disease, Coronary Microvascular Disease, Coronary Microvascular Dysfunction (CMD)
Interventions
Brenzavvy (bexagliflozin), 20 mg Oral Tablet, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Coronary Artery Disease, Chest Pain, Cardiovascular Diseases, Coronary Heart Disease, Angina Pectoris, CAD, CVD, CHD
Interventions
Corus CAD (ASGES)
Diagnostic Test
Lead sponsor
CardioDx
Industry
Eligibility
35 Years to 90 Years
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
Long Beach, California • Roseville, California • Boulder, Colorado + 4 more
Conditions
Pulmonary Hypertension
Interventions
NX1011
Drug
Lead sponsor
NITROX, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Phoenix, Arizona • La Jolla, California • Newark, Delaware + 3 more
Conditions
Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure, HFrEF - Heart Failure with Reduced Ejection Fraction, HFpEF - Heart Failure with Preserved Ejection Fraction, Syncopation, Syncope, Ischemic Cardiovascular Disease, STEMI, STEMI (ST Elevation MI), Atrial Fibrillation (AF), Atrial Enlargement, LVF, Conduction Defect, Conduction Abnormalities, Heart Block, Valvular Diseases, Cardiac Output, Low, Stroke Volume, Stroke Volume Variation, Hyperkalemia, Hypercalcemia, Hypocalcemia, LV Dysfunction, QT Prolongation, Sudden Cardiac Death Due to Cardiac Arrhythmia, Ventricular Arrhythmia, Pacing, Pacing Induced Dyssynchrony, Silent Ischemia, Pericarditis, Sleep Related Breathing Disorder, RSA, Apnea, Obstructive, Cardiac Output Measurement, Respiratory Impedance, CRT And/or ICD, Infarction, Cardiomyopathies, Primary, Hypertrophy
Interventions
SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C, SUBPROTOCOL D, SUBPROTOCOL E, SUBPROTOCOL F, SUBPROTOCOL G, SUBPROTOCOL H
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Melbourne, Florida
Conditions
Asthma, Coronary Artery Disease, Diabetes, Hypertension, Congestive Heart Failure
Interventions
Reports, Reports and Notices, Usual care
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
8,422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Ischemic Heart Disease, Coronary Microvascular Disease, Angina, Myocardial Ischemia
Interventions
CardioFlux
Device
Lead sponsor
Genetesis Inc.
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Gainesville, Florida • Edgewood, Kentucky • Detroit, Michigan + 5 more
Conditions
Coronary Microvascular Dysfunction (CMD), Angina Patients With Non-obstructive Coronary Artery Disease
Interventions
70mL Nitrate Rich Beetroot Juice followed by placebo (Nitrate depleted beetroot juice), Placebo (70 mL Nitrate depleted beetroot juice) followed by 70mL Nitrate Rich Beetroot Juice
Dietary Supplement
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Hypertrophic Cardiomyopathy
Interventions
Eleclazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
Completed Not applicable Interventional Results available

PATient Navigator to rEduce Readmissions

NCT02114515
Conditions
Chronic Obstructive Pulmonary Disease, Heart Failure, Sickle Cell Disease, Myocardial Infarction, Pneumonia
Interventions
Hospital usual care, Navigator intervention, Peer-led telephone support line
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
1,029 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases, Coronary Heart Disease, CAD, CVD, CHD
Interventions
Corus CAD (ASGES)
Diagnostic Test
Lead sponsor
CardioDx
Industry
Eligibility
21 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Gilbert, Arizona • Tempe, Arizona • Woodstock, Georgia + 4 more
Conditions
Obstructive Sleep Apnea, Coronary Heart Disease
Interventions
CPAP, HLSE
Device · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
Interventions
Patients with intermediate coronary artery stenosis with clinically indicated FFR assessment., Microvascular assessment
Procedure
Lead sponsor
AngioInsight
Industry
Eligibility
18 Years and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Minneapolis, Minnesota + 4 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Advancing Understanding of Transportation Options

NCT04141891
Conditions
Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
Interventions
Driving Decision Aid, Older Drivers Website
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Conditions
Ischemic Heart Disease, Coronary Microvascular Disease, Angina
Interventions
CardioFlux Magnetocardiography
Device
Lead sponsor
Genetesis Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Gainesville, Florida • Detroit, Michigan • Cincinnati, Ohio + 1 more
Completed Not applicable Interventional Results available

The Health Access and Recovery Peer Program

NCT01725815
Conditions
Hypertension, Arthritis, Coronary Artery Disease, Hepatitis, Diabetes, Asthma, Hyperlipidemia, HIV
Interventions
HARP Intervention
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Coronary Artery Disease
Interventions
High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily, Lifestyle Counseling, Quality of Life Questionnaires
Drug · Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
2,476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
80
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more
Conditions
Coronary Artery Disease
Interventions
Inclisiran sodium 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
27
States / cities
Huntsville, Alabama • Anchorage, Alaska • Beverly Hills, California + 22 more
Conditions
Cardiovascular Disease, Obstructive Sleep Apnea, Coronary Artery Disease
Interventions
Healthy Lifestyles and Sleep Education plus PAP, Healthy Lifestyles and Sleep Education plus Supplemental Oxygen, Healthy Lifestyles and Sleep Education
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 75 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Cleveland, Ohio
Conditions
Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy, Myocardial Ischemia
Interventions
Losartan
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 13 Years
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Heart Failure, Coronary Disease, Diabetes Mellitus, Asthma, Hypertension, Hypercholesterolemia
Interventions
Community-based nurse care management
Other
Lead sponsor
Health Quality Partners
Other
Eligibility
65 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Doylestown, Pennsylvania
Recruiting Phase 1 Interventional Accepts healthy volunteers

: Vascular Function in Health and Disease

NCT02966665
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions
Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
Other · Drug
Lead sponsor
D. Walter Wray
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Coronary Microvascular Dysfunction, Coronary Microvascular Disease, Microvascular Coronary Artery Disease
Interventions
CLBS16, Placebo
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Gainesville, Florida • Hollywood, Florida + 4 more